NGS Controls & Reference Materials
Somatic Cancer
SHOP PRODUCTSNGS-Based Somatic Cancer Products
SeraCare’s portfolio of Seraseq™ somatic cancer products enables the promise of clinical genomics with the design and manufacture of patient-like reference materials for use in the development, validation, and implementation of molecular next-generation sequencing (NGS) assays that support clinical evaluation and management of cancer diseases.
These clinically relevant reference materials cover the functional areas of:
- Solid tumor profiling
- Liquid biopsy
- Hematological malignancy
- Tumor mutational burden
There are growing numbers of NGS-based tumor profiling assays that are either lab-developed tests (LDTs) or developed by third parties (as RUO or IVD). Clinical implementation of these assays, however, is often hampered by the lack of reference samples with the requisite breadth of clinically relevant genomic alterations and resemblance to patient samples. Seraseq tumor profiling reference materials are highly multiplexed positive sample controls engineered from a blend of biosynthetic targets and well-characterized wild-type background genomic DNA, built to help accelerate the application of NGS technology to the clinical diagnosis and management of various cancer diseases.
Although very important for early diagnosis of cancer, tissue biopsy is invasive, risky, and expensive. The use of blood-based samples to interrogate cancer, i.e., liquid biopsy, has gained importance both as a complementary tool as well as a surrogate sample type for solid tissue biopsies. Seraseq circulating tumor DNA (ctDNA) reference materials were developed to support and accelerate the clinical application of liquid biopsy-based NGS ccfDNA assays.
Hematological, myeloid, malignant cancers are clonal diseases from hematopoietic stem or progenitor cells, and comprises chronic and acute stages. NGS-based myeloid assays are designed to assist in the understanding of somatic changes in patients and can benefit significantly from the use of highly multiplexed, patient-like reference materials such as the Seraseq Myeloid DNA and RNA products.
